Curis, Inc. (NASDAQ:CRIS) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET

Company Participants

Craig West - VP, IR & Corporate Communications

Jim Dentzer - President & CEO

Bill Steinkrauss - CFO & Chief Administrative Officer

Conference Call Participants

Soumit Roy - JonesResearch

Li Watsek - Cantor Fitzgerald

Bob Martell - Head, Research and Development

Operator

Good afternoon, everyone, and welcome to Curis' second quarter 2022 earnings conference call. [Operator instructions] At this time, I'd like to turn the conference over to Curis' vice president of investor relations and corporate communications, Craig West. Sir, please go ahead.

Craig West

Thank you, Jamie, and welcome to Curis' second quarter 2022 earnings call. Before we begin, I would like to encourage everyone to go to the Curis investors section of our website at www.curis.com to find our second quarter 2022 earnings release and related financial tables. I would also like to remind everyone during -- that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially.

For additional details, please see our SEC filings. Joining me on today's call are Jim Dentzer, president and chief executive officer; Bill Steinkrauss, chief financial officer and chief administrative officer; and Bob Martell, head of R&D. We will also be available for a question-and-answer period at the end of the call. I'd now like to turn the call over to Jim. Jim?

Jim Dentzer

Thank you, Craig. Good afternoon, everyone, and welcome to Curis' second quarter earnings call. Every day at Curis, we strive to develop the next generation of first-in-class cancer therapies that meaningfully improve and extend patients' lives. We have several updates for you this quarter.

First, as we've noted previously, the path of drug development is seldom a straight line, and the second quarter began with FDA placing a partial clinical hold on our TakeAim studies in leukemia and lymphoma in April. We're having productive discussions with the agency to bring these discussions to a resolution as quickly as possible. Second, we are delighted to announce that we have appointed a new CFO, which I'll talk about more in a minute. Third, the second quarter also saw several positive presentations on emavusertib at ASCO and EHA, both by our internal team at Curis and by several of our partners in academia with whom we are expanding the frontiers of IRAK4 research.